Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective
Asia Pac J Clin Oncol
.
2021 Apr:17 Suppl 2:3-10.
doi: 10.1111/ajco.13587.
Authors
Michael Michael
1
,
Lorraine Chantrill
2
,
Timothy Price
3
,
David L Chan
4
5
,
Kate Wakelin
6
,
Meredith Cummins
6
Affiliations
1
Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
2
Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia.
3
Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
4
Royal North Shore Hospital, Sydney, New South Wales, Australia.
5
Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
6
NeuroEndocrine Cancer Australia, Melbourne, Victoria, Australia.
PMID:
33851520
DOI:
10.1111/ajco.13587
No abstract available
MeSH terms
Humans
Neuroendocrine Tumors* / drug therapy
Quality of Life*
Grants and funding
Novartis Pharmaceuticals Australia